ストックスクリーナーアプリを入手
89.00
0.96%
-0.865
アフターアワーズ：
88.96
-0.04
-0.04%
前日終値:
$89.86
開ける：
$89.55
24時間の取引高:
389.98K
Relative Volume:
0.54
時価総額：
$7.27B
収益：
$39.21M
当期純損益:
$-311.35M
株価収益率:
-24.19
EPS:
-3.6793
ネットキャッシュフロー:
$-234.34M
1週間 パフォーマンス:
+2.15%
1か月 パフォーマンス:
+12.62%
6か月 パフォーマンス:
+41.52%
1年 パフォーマンス:
+249.57%
1日の値動き範囲:
$87.73
$90.14
1週間の範囲:
$84.19
$90.14
52週間の値動き範囲:
$24.43
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
89.00 | 7.34B | 39.21M | -311.35M | -234.34M | -3.6793 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-06 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 再開されました | Guggenheim | Buy |
| 2025-10-24 | 繰り返されました | B. Riley Securities | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-20 | 再開されました | Stifel | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - MSN
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug - TradingView — Track All Markets
Kymera Therapeutics (KYMR) Receives Fast Track Designation for K - GuruFocus
Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders - Seeking Alpha
RSI Check: What is the earnings history of Kymera Therapeutics IncGap Up & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma - Investing News Network
Kymera Therapeutics (KYMR) Receives Fast Track Designation for KT-621 - GuruFocus
FDA grants fast track status to Kymera’s KT-621 for asthma - Investing.com India
FDA grants fast track status to Kymera’s KT-621 for asthma By Investing.com - Investing.com South Africa
Aug Closing: Can Kymera Therapeutics Inc weather a recession2026 Market Overview & Long-Term Investment Growth Plans - baoquankhu1.vn
Kymera Therapeutics Advances KT-621 with FDA Fast Track Designation for Asthma and Atopic Dermatitis Trials - Quiver Quantitative
FDA Fast Track puts Kymera's once-daily oral asthma drug in focus - Stock Titan
How Investors Are Reacting To Kymera Therapeutics (KYMR) Gilead Option Exercise And US$45M Milestone - Sahm
KYMR SEC FilingsKymera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Gilead expands Tempus AI partnership to boost oncology pipeline - MSN
Discipline and Rules-Based Execution in KYMR Response - Stock Traders Daily
Kymera Therapeutics CBO sells $500k in KYMR stock By Investing.com - Investing.com Australia
Kymera Therapeutics (NASDAQ:KYMR) Insider Noah Goodman Sells 8,264 Shares - MarketBeat
Noah Goodman Sells 2,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics CBO sells $500k in KYMR stock - Investing.com
Kymera Therapeutics (KYMR) CBO trades shares under Rule 10b5-1 plan - Stock Titan
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - Yahoo Finance
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline - Sahm
Gilead exercises option to license Kymera’s KT-200 - BioWorld News
H.C. Wainwright reiterates Kymera Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - Investing News Network
Kymera Therapeutics (NASDAQ: KYMR) brokered sale notice for 11,611 shares - Stock Titan
Gilead Sciences (GILD) Secures Exclusive Rights to KT-200 from K - GuruFocus
Gilead exercises option on Kymera’s CDK2 degrader for $45M By Investing.com - Investing.com South Africa
Gilead exercises option on Kymera’s CDK2 degrader for $45M - Investing.com
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - The Manila Times
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 ... - Bluefield Daily Telegraph
Gilead picks up oral cancer drug KT-200, triggering $45M payout - Stock Titan
CEO Change: Is now the right time to enter Kymera Therapeutics IncEarnings Growth Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Aug PostEarnings: What is the earnings history of Kymera Therapeutics Inc2026 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN
SG Americas Securities LLC Grows Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish - MSN
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - AOL.com
Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $1,251,134.40 in Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares - MarketBeat
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):